Navigation Links
Westaim announces 2009 third quarter results
Date:11/13/2009

-------------------------------------------------------------------- Revenue from continuing operations Nucryst Pharmaceuticals $ 6,672 $ 5,466 $ 17,644 $ 15,428 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (Loss) income from continuing operations Nucryst Pharmaceuticals $ 506 $ (114) $ (1,381) $ (4,133) Other (including corporate costs) (524) (1,737) (2,001) 3,622 ------------------------------------------------------------------------- Loss from continuing operations $ (18) $ (1,851) $ (3,382) $ (511) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Consolidated September 30, December 31, Balance Sheets 2009 2008 -------------------------------------------------- Cash and cash equivalents $ 38,562 $ 46,768 Current assets 50,792 59,783 Other assets 15,891 17,494 Current liabilities 9,002 10,091 Shareholders' equity 46,018 50,002

SOURCE Westaim Corporation


'/>"/>
SOURCE Westaim Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Westaim announces 2009 second quarter results
2. Westaim announces 2009 first quarter results
3. Westaim enters into Management Services Agreement
4. Westaim announces 2008 year-end results
5. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
6. Westaim announces 2008 third quarter results
7. Webcast Advisory - The Westaim Corporation Webcast of Conference Call to Discuss 2008 Third Quarter Results
8. Westaim terminates reorganization agreement and cancels shareholders meeting
9. Westaim to deregister its common stock in the United States
10. Westaim announces sale of iFire Technology Ltd. assets
11. Westaim announces 2008 second quarter results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
(Date:8/21/2014)... The second bellwether trial involving ... has begun in Massachusetts state court. The device ... Law Group LLP, a national personal injury law ... stemming from the implantation of mesh products, provides ... injuries suffered at http://www.wehelpwomen.com/transvaginal-mesh/ . , Maria ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 The ... this year's conference will focus on the Future ... for research, innovation and commercialization. , With the ... SALSS combines the worlds' of business and science. ... widely recognized Summit, gathering a diverse community with ...
(Date:8/21/2014)... two types of polio vaccines seems to provide stronger ... eradicate polio, a new study shows. The research ... the Salk inactivated poliovirus vaccine (IPV) to those who ... vaccine (OPV) appeared to improve their immunity to the ... the Aug. 22 issue of the journal Science ...
(Date:8/21/2014)... 21, 2014. Researchers have published a study examining ... patients with motor complete spinal cord injury (SCI). ... at discharge and follow-up among patients with motor ... on August 2 by the Archives of ... included small but significant differences in self-care and ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2Health News:The Tenth Swedish-American Life Science Summit, takingplace in Stockholm, Sweden, August 20-22nd, will focus on The Future of Medicine 2Health News:Two Polio Vaccines May Give Greater Protection Against Crippling Disease 2Health News:Researchers examine impact of race and ethnicity in motor complete spinal cord injury 2
... with a low-priced antibiotic, according to scientists.It causes severe ... team of scientists at the Liverpool School of Tropical ... in the advanced stages of the disease. In addition, ... Filariasis (LF) affects nearly 120 million people, usually, in ...
... Shepherd Medical Center in Oregon is providing healthy organic food ... Foods from wild salmon to local organic foods are there ... of antioxidant-rich dried cherries. , Angela Mallory, a ... for five days recently for the delivery of her son ...
... is tougher to quit menthol cigarettes than the regular ones, ... in blacks in the U.S.// ,This study was ... black smokers go for menthol cigarettes like Kool or Newport ... several historical and cultural reasons, according to the study. This ...
... increased homicide rates. However as the membership of Alcoholics Anonymous ... number of homicides. In males who consume beer and spirits, ... homicide, a new study finds. ,Results are published ... ,"It is important to try to understand the ...
... Health Department today clarified that so far no chikungunya ... Services T.K. Kuttamani said //that three death attributed to ... ,Mukundan, 71 at Vavallichira, Cherthala ded from ... Selvi, 81, of Kollekkattu also died of natural causes. ...
... the University of Virginia Health System have identified, for the ... carry the genes for nicotine// dependence (ND) in an African ... linkage and included the largest group of African Americans to ... participants in research to find genetic links to ND have ...
Cached Medicine News:Health News:Menthol cigarettes harder to quit than regular cigarettes 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 2Health News:Alcoholics Anonymous: A Blessing For The Addicted 3Health News:Researchers Locate Genetic Link for Nicotine Dependence Among African Americans 2
(Date:8/21/2014)... The Canadian Epilepsy Alliance (CEA) is thrilled to announce the ... about the most common neurological disorder in Canada ... series tells a fictional story based on the experiences of ... epilepsy. "Despite the fact that epilepsy affects ... and lack of awareness out there," says Gail Dempsey ...
(Date:8/21/2014)... N.Y. and HAMBURG, Germany , Aug. 21, 2014 ... is collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a ... , to speed up management and storage of massive ... and Analytics architecture based on IBM software defined ... of data at peak performance and help scientists worldwide ...
(Date:8/21/2014)... announces the list of stocks featured in the Analyst Blog. ... news and events impacting stocks and the financial markets. Stocks ... - Free Report ), IBM (NYSE: IBM - Free ... Report ), GlaxoSmithKline plc (NYSE: GSK - Free Report ... Report ). Today, Zacks is promoting its ,Buy, ...
Breaking Medicine Technology:Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO ) today ... Total revenue was $2.6 million and $8.2 million for the ... million and $3.8 million for the same periods in 2010. ... September 30, 2011, were $9.0 million and $24.0 million as compared ...
... UCB today announced new ... (certolizumab pegol) was associated with a rapid and sustained ... of moderate to severe rheumatoid arthritis (RA) patients. The ... 2011 Annual Scientific Meeting in Chicago, November 5-9, are ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 2New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 3New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 4New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 5New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 6New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 7New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 8New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 9New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 10New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-T 11
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... procedurally specific tip configurations provide maximum ... to all areas of the meniscus ... Graspers feature an infinite position sliding-lock ... tearing or slipping even in ...
... procedurally specific tip configurations provide maximum ... to all areas of the meniscus ... Graspers feature an infinite position sliding-lock ... tearing or slipping even in ...
Medicine Products: